Information Provided By:
Fly News Breaks for December 10, 2019
SGEN
Dec 10, 2019 | 07:38 EDT
Morgan Stanley analyst Matthew Harrison initiated coverage of Seattle Genetics with an Equal Weight rating and $123 price target, stating that while he expects management to execute well and believes the company's oncology pipeline positions it for "robust" growth, he also believes investor expectations are already high.
News For SGEN From the Last 2 Days
There are no results for your query SGEN